Toxicity of hyperthermic intraperitoneal chemotherapy (HIPEC) in pediatric patients with sarcomatosis/carcinomatosis: Early experience and phase 1 results

Pediatric Blood and Cancer

Volumn 59, Issue 2, 2012, Pages 395-397

  Hayes Jordan, A ^a   Green, H ^a   Ludwig, J ^a   Anderson, P ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

Desmoplastic small round cell tumor (DSRCT); HIPEC; Pediatric; Rhabdomyosarcoma (RMS); Sarcomatosis; Wilms' tumor

Indexed keywords

CISPLATIN;

ADOLESCENT; ADULT; ARTICLE; CANCER CHEMOTHERAPY; CARCINOMATOSIS; CARDIOTOXICITY; CHILD; CHILDHOOD CANCER; CLINICAL ARTICLE; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOREDUCTIVE SURGERY; DRUG DOSE ESCALATION; DRUG TOLERANCE; FOLLOW UP; HEMATOLOGIC DISEASE; HUMAN; HYPERTHERMIC INTRAPERITONEAL CHEMOTHERAPY; ILEUS; KIDNEY FAILURE; LIVER TOXICITY; POSTOPERATIVE COMPLICATION; PRESCHOOL CHILD; PRIORITY JOURNAL; SARCOMA; SARCOMATOSIS; SCHOOL CHILD; SURGICAL INFECTION; SURGICAL MORTALITY;

ADENOCARCINOMA; ADOLESCENT; ADULT; ANTINEOPLASTIC AGENTS; CARDIOVASCULAR DISEASES; CHEMOTHERAPY, CANCER, REGIONAL PERFUSION; CHILD; CHILD, PRESCHOOL; CISPLATIN; COHORT STUDIES; COMBINED MODALITY THERAPY; FEMALE; FOLLOW-UP STUDIES; HEMATOLOGIC DISEASES; HUMANS; HYPERTHERMIA, INDUCED; LIVER DISEASES; MALE; MAXIMUM TOLERATED DOSE; NEOPLASM STAGING; PROGNOSIS; SARCOMA; YOUNG ADULT;

EID: 84862263182     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.24160     Document Type: Article

References (28)

1. Verwaal VJ, Bruin S, Boot H, et al. 8-year follow-up of randomized trial: Cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008; 15: 2426- 2432.
2. Esquivel J, Sticca R, Sugarbaker P, et al. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy in the management of peritoneal surface malignancies of colonic origin: A consensus statement. Society of Surgical Oncology. Ann Surg Oncol 2007; 14: 128- 133.
3. Gonzalez-Moreno S. Peritoneal surface oncology: A progress report. Eur J Surg Oncol 2006; 32: 593- 596.
4. Roviello F, Caruso S, Marrelli D, et al. Treatment of peritoneal carcinomatosis with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: State of the art and future developments. Surg Oncol 2010; 20: e38- e54.
5. Fujimoto S, Takahashi M, Mutou T, et al. Successful intraperitoneal hyperthermic chemoperfusion for the prevention of postoperative peritoneal recurrence in patients with advanced gastric carcinoma. Cancer 1999; 85: 529- 534.
6. Yonemura Y, de Aretxabala X, Fujimura T, et al. Intraoperative chemohyperthermic peritoneal perfusion as an adjuvant to gastric cancer: Final results of a randomized controlled study. Hepatogastroenterology 2001; 48: 1776- 1782.
7. Yan TD, Welch L, Black D, et al. A systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for diffuse malignancy peritoneal mesothelioma. Ann Oncol 2007; 18: 827- 834.
8. Lim SJ, Cormier JN, Feig BW, et al. Toxicity and outcomes associated with surgical cytoreduction and hyperthermic intraperitoneal chemotherapy (HIPEC) for patients with sarcomatosis. Ann Surg Oncol 2007; 14: 2309- 2318.
9. Hayes-Jordan A, Anderson P, Curley S, et al. Continuous hyperthermic peritoneal perfusion for desmoplastic small round cell tumor. J Pediatr Surg 2007; 42: E29- E32.
10. Reingruber B, Boettcher MI, Klein P, et al. Hyperthermic intraperitoneal chemoperfusion is an option for treatment of peritoneal carcinomatosis in children. J Pediatr Surg 2007; 42: E17- E21.
11. Msika S, Gruden E, Sarnacki S, et al. Cytoreductive surgery associated to hyperthermic intraperitoneal chemoperfusion for desmoplastic round small cell tumor with peritoneal carcinomatosis in young patients. J Pediatr Surg 2010; 45: 1617- 1621.
12. Glehen O, Gilly FN, Boutitie F, et al. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: A multi-institutional study of 1, 290 patients. Cancer 2010; 116: 5608- 5618.
13. Rossi CR, Mocellin S, Pilati P, et al. Pharmacokinetics of intraperitoneal cisplatin and doxorubicin. Surg Oncol Clin N Am 2003; 12: 781- 794.
14. Rossi CR, Deraco M, De Simone M, et al. Hyperthermic intraperitoneal intraoperative chemotherapy after cytoreductive surgery for the treatment of abdominal sarcomatosis: Clinical outcome and prognostic factors in 60 consecutive patients. Cancer 2004; 100: 1943- 1950.
15. Markman M. Intraperitoneal antineoplastic drug delivery: Rationale and results. Lancet Oncol 2003; 4: 277- 283.
16. Casper ES, Kelsen DP, Alcock NW, et al. Ip cisplatin in patients with malignant ascites: Pharmacokinetic evaluation and comparison with the iv route. Cancer Treat Rep 1983; 67: 235- 238.
17. Howell SB, Pfeifle CL, Wung WE, et al. Intraperitoneal cisplatin with systemic thiosulfate protection. Ann Intern Med 1982; 97: 845- 851.
18. (NCI) NCI. Common Terminology Criteria for Adverse Events (CTCAE). 2009: v4.03 June 14, 2010.
19. Sugarbaker PH, Alderman R, Edwards G, et al. Prospective morbidity and mortality assessment of cytoreductive surgery plus perioperative intraperitoneal chemotherapy to treat peritoneal dissemination of appendiceal mucinous malignancy. Ann Surg Oncol 2006; 13: 635- 644.
20. Park BJ, Alexander HR, Libutti SK, et al. Treatment of primary peritoneal mesothelioma by continuous hyperthermic peritoneal perfusion (CHPP). Ann Surg Oncol 1999; 6: 582- 590.
21. Yan TD, Edwards G, Alderman R, et al. Morbidity and mortality assessment of cytoreductive surgery and perioperative intraperitoneal chemotherapy for diffuse malignant peritoneal mesothelioma-a prospective study of 70 consecutive cases. Ann Surg Oncol 2007; 14: 515- 525.
22. de Bree E, Romanos J, Michalakis J, et al. Intraoperative hyperthermic intraperitoneal chemotherapy with docetaxel as second-line treatment for peritoneal carcinomatosis of gynaecological origin. Anticancer Res 2003; 23: 3019- 3027.
23. Farma JM, Pingpank JF, Libutti SK, et al. Limited survival in patients with carcinomatosis from foregut malignancies after cytoreduction and continuous hyperthermic peritoneal perfusion. J Gastrointest Surg 2005; 9: 1346- 1353.
24. Kunisaki C, Shimada H, Akiyama H, et al. Therapeutic outcomes of continuous hyperthermic peritoneal perfusion against advanced gastric cancer with peritoneal carcinomatosis. Hepatogastroenterology 2006; 53: 473- 478.
25. Feldman AL, Libutti SK, Pingpank JF, et al. Analysis of factors associated with outcome in patients with malignant peritoneal mesothelioma undergoing surgical debulking and intraperitoneal chemotherapy. J Clin Oncol 2003; 21: 4560- 4567.
26. Yan TD, Black D, Savady R, et al. Systematic review on the efficacy of cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for peritoneal carcinomatosis from colorectal carcinoma. J Clin Oncol 2006; 24: 4011- 4019.
27. Cotte E, Colomban O, Guitton J, et al. Population pharmacokinetics and pharmacodynamics of cisplatinum during hyperthermic intraperitoneal chemotherapy using a closed abdominal procedure. J Clin Pharmacol 2010; 51: 9- 18.
28. Kusamura S, Baratti D, Younan R, et al. Impact of cytoreductive surgery and hyperthermic intraperitoneal chemotherapy on systemic toxicity. Ann Surg Oncol 2007; 14: 2550- 2558.